title: Induction of lithostathine/reg mRNA expression by serum from rats with acute pancreatitis and cytokines in pancreatic acinar AR-42J cells.
abstract: During the acute phase of pancreatitis, expression of most pancreatic enzymes decreases, whereas mRNAs of pancreatitis associated protein and lithostathine/reg increase dramatically. In the present study we have investigated the effect of serum from rats with acute pancreatitis (SAP) and cytokines on the lithostathine/reg mRNA expression in AR-42J cells. Lithostathine/reg mRNA was strongly induced by SAP in a dose-dependent manner. Induction was abolished by preheating the SAP or by treating the cells with cycloheximide. Treatment with interleukins (IL) IL-1 or IL-6 or dexamethasone alone was ineffective. Combination of IL-1 with IL-6 was also ineffective. Combination of IL-6 with dexamethasone resulted in strong induction of the lithostathine/reg gene, but the further addition of IL-1 to the mixture reduced induction. Treatment with tumor necrosis factor-alpha (TNFalpha) or interferon-gamma (IFNgamma) induced lithostathine/reg mRNA expression. Combination of dexamethasone with TNFalpha or IFNgamma showed an inhibitory effect on lithostathine/reg mRNA expression. These findings suggest that expression of the lithostathine/reg mRNA during acute pancreatitis could be mediated by specific combinations of cytokines and/or glucocorticoids.
authors.affiliation: U.315 INSERM, Marseille, France.
authors.forename: N J
authors.initials: NJ
authors.lastname: Dusetti
authors.forename: G V
authors.initials: GV
authors.lastname: Mallo
authors.forename: E M
authors.initials: EM
authors.lastname: Ortiz
authors.forename: V
authors.initials: V
authors.lastname: Keim
authors.forename: J C
authors.initials: JC
authors.lastname: Dagorn
authors.forename: J L
authors.initials: JL
authors.lastname: Iovanna
mesh_terms: D000208:Acute Disease; D000818:Animals; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D002417:Cattle; D002460:Cell Line; D003470:Culture Media; D003513:Cycloheximide / Q000494:pharmacology; D016207:Cytokines / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D051847:Lithostathine; D009419:Nerve Tissue Proteins; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010195:Pancreatitis / Q000097:blood* / Q000139:chemically induced; D000073718:Pancreatitis-Associated Proteins; D010750:Phosphoproteins / Q000096:biosynthesis; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013656:Taurocholic Acid; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D002135:Calcium-Binding Proteins; D003470:Culture Media; D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D051847:Lithostathine; D009419:Nerve Tissue Proteins; D000073718:Pancreatitis-Associated Proteins; D010750:Phosphoproteins; C000612141:REG3A protein, human; D012333:RNA, Messenger; C497616:Reg1a protein, rat; D013656:Taurocholic Acid; D003907:Dexamethasone; D003513:Cycloheximide